An Integral Platform for the Early Diagnosis of Skin Cancer
DermoSafe® is an integral platform based on DermoBrain, a cognitive computing system which will enable the early
detection of skin cancer for broad population. The ICT-based approach facilitates and speeds the professional analysi...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto DermoSafe 2.0
Duración del proyecto: 4 meses
Fecha Inicio: 2018-11-19
Fecha Fin: 2019-03-31
Líder del proyecto
DermoSafe SA
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
DermoSafe® is an integral platform based on DermoBrain, a cognitive computing system which will enable the early
detection of skin cancer for broad population. The ICT-based approach facilitates and speeds the professional analysis of
potential skin lesion by employing Dermoscopy Imaging. DermoSafe provides an accurate tool that allows patient performing
the needed increased analysis to combat the exploded incidence of skin cancer without the requirement of an appointment
with general practitioners or dermatologists, reducing lead time of the skin analysis results from 42 to 3 days. Hence, patient
uncertainty and anxiety is clearly diminished. Furthermore, DermoSafe enables a fast and easy access to Dermoscopy
experts to the healthcare professional community (pharmacies, general practitioners and dermatologists). DermoSafe has
demonstrated capability to overpass the limitations posed by current Dermoscopy devices for early and broad screening by
avoiding the need of a high investment to buy the equipment as well as offsets the lack of specialised dermatology
workforce. Once implemented in the healthcare system and at pharmacies, DermoSafe can reduce the skin cancer budget
up to 136,000€/patient. Since our platform and associated service will make the use of Dermoscopy imaging as broad as the
use of a thermometer, the business opportunity seems unquestionable. The objective of this project is the further
development of DermoBrain, to enable (1) skin lesion pattern recognition and identification for automatic history tracking and
evolution rating, (2) automatic image quality check, and (3) image automatic classification considering also the patient
medical context by artificial intelligence. By deploying DermoSafe platform in Europe, we aim to achieve a cumulative cash
flow of 10.7 M€ by 2024, resulting in a ROI of 4.2